DOI: http://dx.doi.org/10.18203/2349-2902.isj20220933

The study of gangrenous large bowel in COVID-19 patient in our institute an observational study

Niraj Bhusakhare, Rahul Singh, Vinod Singh, Sanjay Goyal, Jogesh Chandra Marhual, Samir Kathale

Abstract


Initially considered to be a respiratory disease, COVID-19 is now recognized as a multisystem disease known to affect all the major organs, including the gastrointestinal system. Based on recent studies, coronavirus 2 causes dysregulation of multiple biological pathways, triggers an exaggerated immune response, and affects multiple organs. The gastrointestinal symptoms in COVID-19 are common but often overlooked. This is an observational study analyzing the clinical characteristics and outcomes of three COVID-19 patients aged 80-year, 75-year, 69-year presented to our institution from April 2021 to June 2021 and were diagnosed with COVID-19 and subsequently develop perforation peritonitis and gangreneos large bowel as a first presentation. All patients tested COVID-19 positive upon admission and received standard care.

 


Keywords


COVID-19, Gangrenous bowel, Gastrointestinal system

Full Text:

PDF

References


Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157-60.

Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease, 2019 in China. N Engl J Med. 2020;382(18):1708-20.

Chen T, Wu D, Chen H. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.

Thachil J, Tang N, Gando S. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-6.

Klok FA. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7.

Lodigiani C. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14.

COVID-19 Treatment Guidelines Panel, Coronavirus Disease 2019 (COVID-19)Treatment Guidelines, National Institutes of Health, 2020, Available at: https://www.covid19treatmentguidelines.nih.gov/. Accessed on 10 February 2021.

Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K, Thromboembolic risk and anticoagulant therapy in COVID-19patients: emerging evidence and call for action. Br J Haematol. 2020;189(5):846-7.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-9.

Mortus JR, Manek SE, Brubaker LS. Thromboelastographic results andhypercoagulability syndrome in patients with coronavirus disease 2019 who are critically ill. JAMA Netw Open. 2020;3(6):e2011192.

Mao R, Qiu Y, He JS. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:667-78.

Varga Z, Flammer AJ, Steiger P. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-8.

Magro C, Mulvey JJ, Berlin D. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1-13.

McGonagle D, Bridgewood C, Ramanan AV, Meaney JFM, Watad A: COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol. 2021;3:224-33.

Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020;69:1181-9.

Lippi G, Sanchis-Gomar F, Favaloro EJ, Lavie CJ, Henry BM: Coronavirus disease 2019-associated coagulopathy. Mayo Clin Proc. 2021;96:203-17.

Khesrani LS, Chana K, Sadar FZ, Dahdouh A, Ladjadj Y, Bouguermouh D. Intestinal ischemia secondary to COVID-19. J Pediatr Surg Case Rep. 2020;61:101604.